Finnish biotechnology company NADMED has announced the launch of the NADMED Award 2026 in the hope of generating new discoveries in the field of metabolomics.
The award’s goal is to empower scientists and clinicians to investigate key cellular processes linked to metabolism, ageing and disease. By providing access to its advanced metabolomics platform, NADMED hopes to encourage discovery, collaboration and innovation across the biomedical sector.
The award is comprised of three categories, designed to support different stages of product development. These are Innovative Ideas, Advanced Research and Clinical Data Research. The Award is open to applications from academic institutions, clinical laboratories, pharmaceutical companies and biotechnology innovators, with submissions judged by a panel of global experts. Winning projects will receive CE-marked metabolomics kits, expert consultation and in-house measurement services valued at up to $30,000.
The results of the NADMED Award 2026 will be announced on 28 February 2026.
“The goal of the NADMED Award is to lower the barriers for scientists to explore what has until now been largely invisible in biology: the dynamics of redox metabolism,” Kai Herdin, chief marketing officer at NADMED, said. “By making our tools available to the research community, we want to accelerate discoveries that could transform how we understand cellular function and disease.”
Founded in 2022 from the University of Helsinki, NADMED’s technology is capable of quantifying all four forms of nicotinamide adenine dinucleotide and both reduced and oxidized glutathione directly from biological samples. It has the potential to uncover valuable diagnostic insights across the research and clinical sectors.
Professor Charles Brenner, a member of the NADMED Award jury, said: “This award is a powerful way to stimulate discovery across multiple fields of biology and medicine.”
